Registration Options

Activity Dates: 10/10/2024 - 07/10/2025

Target Audience

BCPPs desiring an evidence-based focus on emerging areas of practice and contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who learn best from didactic presentations, are auditory and visual learners, and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.


The Summit is an application-based continuing pharmacy education (CPE) activity designed to advance the knowledge and improve competency of participants through the delivery of evidence-based presentations on emerging areas of practice and contemporary issues in psychiatric pharmacy. This two-day, interactive, virtual conference provides knowledge and tools to improve the comprehensive care of patients with mental health disorders. The content is valuable to all psychiatric pharmacists regardless of the practice setting.
An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned, at the expected level of practice of Board Certified Psychiatric Pharmacists. The examination for this product often features cases requiring that the participant apply the principles learned through the presentations.
The Summit includes:
  1. Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live during the Virtual Summit, October 10-11, 2024).
  2. For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online AAPP recertification examination.
  3. Access to the AAPP testing center with exam submission due on or before July 10, 2025.

Learning Objectives

Management of Attention-Deficit/Hyperactivity Disorder (ADHD): Considerations for Adults and Stimulant Shortages

  1. Evaluate adult patients for attention-deficit/hyperactivity disorder (ADHD) using screening tools and rating scales.
  2. Formulate treatment plans for adult patients with ADHD.
  3. Identify appropriate stimulant medication alternatives during a medication shortage.
You and Me versus ChatGPT
  1. Outline how artificial intelligence programs can be used to enhance patient care.
  2. Recognize limitations and ethical concerns associated with using artificial intelligence programs in healthcare.
  3. Identify next steps for integrating artificial intelligence into clinical pharmacy practice in psychiatry.
Benzodiazepine-Induced Neurological Dysfunction
  1. Identify a patient with benzodiazepine-induced neurological dysfunction (BIND).
  2. Determine risk factors and prevention strategies for development of BIND.
  3. Examine risk factors for developing BIND.
  4. Create a treatment plan for management of BIND.
Impact of Microaggressions on Practice
  1. Identify microaggressions impacting vulnerable populations. 
  2. Assess the impact of microaggressions on the provision of optimal patient care. 
  3. Propose strategies to address microaggressions in a clinical setting.  
Chronic Pain and Depression/Anxiety: Addressing the Cycle
  1. Evaluate the relationship between chronic pain and mental health conditions, such as depression and anxiety.
  2. Identify patients with chronic pain, who are also experiencing depression, anxiety and/or suicidal ideation, using validated instruments.
  3. Recommend appropriate pharmacologic and/or non-pharmacologic treatments for patients experiencing comorbid chronic pain and depression/anxiety when presented with a patient case.
Managing Pain and Co-Occurring Opioid Disorder: Dispelling Myths to Improve Care
  1. Evaluate the risks of undertreated pain for patients with co-occuring opioid use disorder.  
  2. Design a treatment plan to address co-occurring chronic pain and opioid use disorder. 
  3. Choose treatments for acute pain in individuals receiving medication for opioid use disorder.
Use of Psychedelics for the Treatment of Substance Use Disorders
  1. Analyze evidence for psychedelics in the treatment of substance use disorders.
  2. Describe best practices for psychedelic implementation into substance use disorder treatment.
  3. Formulate a comprehensive treatment plan for patients undergoing psychedelic assisted therapy for a substance use disorders.
Street Medicine: Psychiatric Care for Individuals who are Unhoused
  1. Identify barriers to medication access for individuals who are unhoused.
  2. Propose rationale for use of street medicine in the treatment of individuals who are unhoused with psychiatric illness.
  3. Assess the role of health care team members, including psychiatric pharmacists, in street medicine teams.

Continuing Education Credit and Disclosures

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.

The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.